Non Hodgkin Lymphoma Clinical Trial
A Study of JNJ-90014496 in Participants With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Summary
This is a Phase Ib multicenter, open-label study of C-CAR039, an autologous bi-specific CAR-T therapy targeting CD19 and CD20, for the treatment of adult patients with relapsed or refractory B-Cell non-Hodgkin lymphoma (r/r B-NHL).
Eligibility Criteria
Participant must be greater than or equal to (>=) 18 years of age, at the time of signing informed consent
Diagnosis of mature aggressive large B cell non-Hodgkin lymphoma or follicular lymphoma
Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive
Must have relapsed or refractory disease with the following indications for each histologic subtype: Mature aggressive large B cell non-Hodgkin lymphoma (NHL) and follicular lymphoma Grade 3b: Participants must have >= 2 lines of systemic therapy, or >= 1 line of systemic therapy for participants who are ineligible for autologous stem cell transplant; Follicular lymphoma Grade 1-3a and marginal zone lymphoma: Participants must have >= 2 prior lines of anti-neoplastic systemic therapy. Participants also must have prior exposure to an anti-CD20 monoclonal antibody
Measurable disease as defined by Lugano 2014 classification
Eastern cooperative oncology group (ECOG) performance status of either 0 or 1
Exclusion Criteria
Diagnosis of Human herpes virus (HHV) 8-positive diffuse large B Cell lymphoma (DLBCL)
Prior allogeneic hematopoietic stem cell transplantation (HSCT)
Autologous stem cell transplant within 12 weeks of chimeric antigen receptor (CAR) T cell infusion
Uncontrolled active infections
History of deep vein thrombosis or pulmonary embolism within six months of infusion (except for line associated deep vein thrombosis [DVT])
History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of screening
History of a seizure disorder, cerebrovascular ischemia/hemorrhage, dementia, cerebellar disease or neurodegenerative disorder
Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system
Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 10 Locations for this study
Duarte California, 91010, United States
Denver Colorado, 80218, United States
Piscataway New Jersey, 08854, United States
Pittsburgh Pennsylvania, 15232, United States
Austin Texas, 78704, United States
San Antonio Texas, 78229, United States
Seattle Washington, 98104, United States
Fitzroy , 3065, Australia
Melbourne , 3004, Australia
Murdoch , 6150, Australia
How clear is this clinincal trial information?